id.DRIVE is a public-private partnership made up of a unique consortium of pharmaceutical companies, public health institutes, and research groups who are joining forces to monitor infectious diseases and the real-world effectiveness of related pharmaceutical products in Europe. This is achieved by several pharmaceutical companies co-funding a research network of hospitals.

id.DRIVE leverages the COVID-19 vaccine effectiveness (VE) platform COVIDRIVE (2021-2023) and the influenza VE platform DRIVE (2017-2022). The partnership decided to use the established consortium and study network to expand its scope to all infectious diseases (IDs), lending its name to the new partnership. In addition to vaccines, other pharmaceutical products such as antivirals and monoclonal antibodies will be studied.

While id.DRIVE will continue performing COVID-19 effectiveness studies, the consortium will initiate a first surveillance study starting mid-2024 on many other respiratory pathogens, such as influenza, RSV, adenovirus, human enterovirus, and parainfluenza virus. This surveillance will help to understand the impact of these respiratory pathogens on serious illness, and to monitor the effectiveness of pharmaceutical products that are or will be available to prevent and cure these viral illnesses.

The id.DRIVE public-private partnership includes eight partners: pharmaceutical company partners AstraZeneca, Janssen, GSK, Novavax, Valneva, and Pfizer; P95, a small and medium enterprise; and Fisabio, a Spanish regional public health institute. The id.DRIVE study network covers 13 European countries and comprises 32 study contributors, five primary care networks, and a nationwide register. id.DRIVE is open to new partners and is expanding its study network.

To join id.DRIVE as a partner or study site, contact info@idDRIVE.org. Find out more at iddrive.eu.

About AKEURA

AKEURA is a specialist contract research organization (CRO) with dual expertise in clinical and real-world settings, from early- through late-phase clinical development to real-world evidence (RWE). With more than 25 years of experience and more than 500 researchers, clinicians, and scientists across five continents, AKEURA helps sponsors advance medicines across their full lifecycle, with an exclusive focus on three therapeutic areas: neuroscience, infectious diseases and vaccines, and cardiometabolic diseases. In each, it brings the experience, reach, and hands-on expertise to give every promising medicine the study it deserves. Formerly P95 Julius Clinical, AKEURA is headquartered in Zeist, the Netherlands, and backed by Ampersand Capital Partners. Learn more at akeura.com.